10x Genomics, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-07.
0001628280-26-054491
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-06.
0001628280-26-071199
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 2 previous paragraphs and 463 current paragraphs.
1 unchanged; 0 reworded; 462 added; 1 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (462)
Current report
Investing in our Class A common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report and in the Annual Report on Form 10-K that we filed with the U.S. Securities and Exchange Commission (“SEC”) on February 12, 2026, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our Class A common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows and prospects. In such an event, the market price of our Class A common stock could decline and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our Class A common stock. In addition, you should consider the interrelationship and compounding effects of multiple risks occurring simultaneously.
Current report
Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully below and include, but are not limited to, risks related to:
Current report
•Fluctuations in our operating results due to a variety of factors;
Current report
•Our dependency on the availability of funding, including government funding and research and development spending by research institutions;
Current report
•Our ability to develop new products or new versions of existing products and enhance the capabilities of our existing products;
Current report
•Our ability to effectively manage product transitions and forecast customer demand, including for both existing and newly introduced products, including production ramp of our Atera platform, and the risk that new products or new versions of existing products, including Atera, cannibalize or adversely affect the sales of our existing products;
Current report
• Our strategy to enter the clinical and diagnostic markets, including the establishment and operation of a clinical laboratory and the development of laboratory developed tests;
Current report
•Trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers, and geopolitical conflict, including military conflict in the Middle East;
Current report
•Our ability to increase penetration into our existing customer segments and to maintain and increase the effectiveness of our commercial organization;
Current report
•Our ability to generate sufficient revenue, to attain cash flows from operating activities in excess of our capital investment requirements and to achieve and maintain profitability;
Current report
•The complexity of data generated by our products and risks related to our development, use and sale of artificial intelligence technologies and the extent to which demand for our products is driven by the use of our data to develop artificial intelligence models;
Current report
•Our ability to consistently manufacture our products to necessary specifications in necessary quantities and at acceptable cost and performance level;
Current report
•Our dependency on revenue generated from the sale of our Chromium solutions;
Current report
•Doing business internationally, including in China and elsewhere in the Asia-Pacific region, and exposure to interest and foreign currency exchange rates;
Current report
•The ability of suppliers to meet our needs and the needs of our customers;
Current report
•The complexity of our operations and manufacturing our products, including in sourcing raw materials and preventing errors and defects in our solutions;
Current report
•Our limited operating history, losses since inception, fluctuations in revenue and management of growth; and
Current report
•The success of our products in achieving and sustaining scientific acceptance and generating revenue.
Current report
Risks related to our regulatory environment and taxation:
Current report
•Our products could become subject to more onerous government regulation by the FDA or other regulatory agencies;
Current report
•Changes in tax laws or regulations that are applied adversely to us or our customers; and
Current report
•Ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing.
Current report
Risks related to our intellectual property, information technology and data security:
Current report
•Our ability to obtain, maintain and protect our intellectual property rights; and
Current report
•Our dependence on certain intellectual property rights that are licensed to us.
Current report
Risks related to litigation and our intellectual property:
Current report
•Our potential involvement in lawsuits in connection with intellectual property rights; and
Current report
•Our ability to effectively protect and enforce our intellectual property rights.
Current report
•The multi-class structure of our common stock; and
Current report
•The requirement of our bylaws that the State of Delaware is the exclusive forum for substantially all disputes between us and our shareholders.
Current report
•Our ability to meet our publicly announced guidance or other expectations about our business; and
Current report
•The volatility of the market price of our Class A common stock.
Current report
The summary risk factors described above should be read together with the text of the full risk factors below in this section titled “Risk Factors” and the other information set forth in this Quarterly Report on Form 10-Q, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future prospects.
Showing the first 40 of 462 passages. Open the source sections for the rest.
Removed paragraphs (1)
Previous report
There have been no material changes to our risk factors that we believe are material to our business, results of operations and financial condition from the risk factors previously disclosed in our Annual Report, and any documents incorporated by reference therein, which are accessible on the SEC’s website at www.sec.gov.